CDKN2A and leukemia: Recent dermatopathology studies illustrated the major utility of immunohistochemistry in the correct and exhaustive diagnosis of malignant melanocytic tumors, indicating that patients with loss of p16 expression were associated with significantly lower survival rates [14], a finding congruent with those noted in studies exploring other tumoral categories, such as pancreatic carcinoma [15], leukemias [16], and pulmonary carcinoma [17], where p16 alterations are corroborated with superior tumoral aggressivity and unfavorable prognosis.